This research study is currently not recruiting patients.

A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer



Study Overview

his randomized phase II trial studies radiation therapy to see how well it works in treating patients with prostate cancer.


Study Description

The purpose of this study is to demonstrate that 1-year health-related quality of life (HRQOL) for at least one hypofractionated arm is not significantly lower than baseline as measured by the Bowel and Urinary domains of the Expanded Prostate Cancer Index Composite (EPIC) instrument.

Research Study Identifier: TX2472
ClinicalTrials.gov Identifier: NCT1204008432 (RTOG0938)
Principal Investigator: Peter Johnstone


Not Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.